Effect of duration of diabetes on bone mineral density: a population study on East Asian males

Miso Jang, Hyunkyung Kim, Shorry Lea, Sohee Oh, Jong Seung Kim and Bumjo Oh

Abstract

Background: The aim of the present study is to evaluate the association between BMD and type 2 DM status in middle-aged and elderly men. To investigate a possible correlation, the present study used the BMD dataset of the Korea National Health and Nutrition Examination Survey (KNHANES) from 2008 to 2011.

Methods: In total, 37,753 individuals participated in health examination surveys between 2008 and 2011. A total of 3383 males aged ≥50 years were eligible. They underwent BMD measurement through dual-energy X-ray absorptiometry (DXA). The fasting plasma glucose and insulin levels of participants were also measured.

Results: Men with prediabetes and diabetes had significantly higher mean BMD at all measured sites than control men did, irrespective of DM status. This was confirmed by multivariable linear regression analyses. DM duration was an important factor affecting BMD. Patients with DM for > 5 years had lower mean BMD in the total hip and femoral neck than those with DM for ≤5 years. Per multivariable linear regression analyses, patients with DM for > 5 years had significantly lower mean BMD at the femoral neck than those with DM ≤5 years.

Conclusions: DM duration was significantly associated with reduced femoral neck BMD.

Keywords: Diabetes mellitus, Prediabetic state, Bone mineral density, Dual-energy X-ray absorptiometry, Osteoporosis, Korea National Health and nutritional examination survey

Background

Type 2 diabetes mellitus (DM) is a common metabolic disease with an increasing worldwide prevalence rate of 8.3% [1], and with 11% among Korean male adults. Considering that more than 9 million osteoporotic fractures are recorded annually worldwide, osteoporosis is a significant contributor to morbidity and lost life years globally [2]. Osteoporosis and type 2 DM share many common characteristics in that they are both chronic diseases with an increasingly global medical burden.

Although individuals with type 1 DM show decreased bone mass density (BMD), those with type 2 DM often have normal or even slightly elevated BMD compared with an age-matched control population [3]. Bone fragility results from decreased bone mineral mass and alterations in bone microstructure. Multiple mechanisms can contribute to increased fractures in type 2 DM patients. Glucose toxicity, lack of insulin and other factors affects bone metabolism. A substantial number of studies examined the association between type 2 DM and fracture risk [4, 5]. Longer type 2 DM duration increases diabetic complications, insulin usage, and fracture risk and results in inadequate glucose control. Clinically, assessing the bone microstructure of type 2 DM patients is difficult because CT or MRI should be used [3]. Therefore determining the BMD is the best approach for now.

The prevention of fractures is an important goal for studies concerning older adults. Many studies focus on osteoporosis in women. However, as many as one in four men aged >50 years will develop at least one osteoporosis-related fracture in his lifetime, highlighting the need for more studies on osteoporosis in men [6]. One in three men die in within a year after a hip fracture, another one in three experience a subsequent fracture.
fracture again [7]. Generally, men have worse smoking and alcohol drinking habits and higher risk of fall than women [8], which may contribute to bone health deterioration. Furthermore, men are approximately 70% less frequently screened for osteoporosis than women [9]. For individuals aged ≥50 years in Korea, the prevalence rates of osteoporosis and osteopenia are 7.3% and 38.0% in men and 46.5% and 48.7% in women, respectively [10]. In another Korean study, only 7.6% of men found out that they had osteoporosis, and only 5.7% of them had their disease treated [11].

In light of public health, male osteoporosis associated with type 2 DM should be carefully considered. The present study aimed to assess the association between BMD and type 2 DM status by considering several confounding factors such as age, body mass index (BMI), and fasting insulin and glucose level. We hypothesized that participants with longer duration of type 2 DM may have lower BMD because of poor disease control and insulin deficiency.

**Methods**

**Study design and participants**
The Korea National Health and Nutritional Examination Survey (KNHANES) is a nationwide survey representing the non-institutionalized civilian population of South Korea. The Division of Health and Nutritional Survey of the Korea Centers has periodically conducted it for Disease Control and Prevention (KCDCP) since 1998. The data from KNHANES is open data for research purposes. A complex, stratified, multilevel probability sampling design was used, and sampling units were selected based on geographical area, age and sex [12]. Each sampled participant is assigned a numerical sample weight that measures the number of populations represented by that specific participant [12]. A complex sampling design and sample weights facilitate the production of nationally representative data [13]. The KNHANES consists of three components: a health interview, a nutrition survey, and a health examination. Until the first half of 2008, data were gathered through household interviews and direct standardized physical examinations conducted at simple checkup centers at city government offices and town halls [14]. From the second half of 2008 to 2011, the survey was conducted by introducing mobile inspection vehicles. In July 2008, the whole-body dual-energy x-ray absorptiometry (DXA) survey was newly introduced and tested until May 2011. People who were tested before July 2008 and after May 2011 have not received the DXA. From 2008 to 2011, the KNHANES included 37753 individuals. Of the 5872 male participants who were aged ≥50 years, 2489 were eliminated from the study based on the following exclusion criteria: missing data, fasting time of <8 h, taking prescription medication for osteoporosis, and the questionnaire answered with having been diagnosed and treated by physicians for the conditions affecting bone metabolism, such as all types of cancer, chronic kidney disease, liver cirrhosis, thyroid disease, or rheumatoid arthritis (Fig. 1). After all exclusions, 3383 participants were finally included in this analysis.

**Associated factors**
As described previously [12], the demographic and behavior variables were age, monthly house income, smoking (never, past, or current smoker), alcohol drinking (grams of alcohol per day), and physical activity (low, moderate, or high). The average alcoholic beverage intake was assessed by self-reported questionnaire and then converted to the amount of pure alcohol (in grams) consumed per day. Physical activity was quantified as the metabolic equivalent of task (MET) minutes per week calculated using the Korean version score calculation of the short-form International Physical Activity Questionnaire. Therefore, physical activity levels were then classified as low (<600 MET minutes per week), moderate (600 ≤ <3000 MET minutes per week), or high (≥3000 MET minutes per week) [12].

Standardized techniques and equipment were used to measure height and weight, and body mass index (BMI) was calculated by dividing body weight by the square of height (kg/m²) [14]. Blood pressure (BP) was measured by a standard method using a sphygmomanometer in a sitting position. The following definition for hypertension was obtained from the Division of Health and Nutritional Survey under the KCDCP: either by a self-reported history of hypertension diagnosis and current usage of antihypertensive drug or by ≥140 mmHg systolic BP or ≥90 mmHg diastolic BP.

**Laboratory examinations**
During the survey, in the morning, blood samples were collected and analyzed by a certified central laboratory. Plasma total cholesterol (milligrams per deciliter), high-density lipoprotein (HDL) cholesterol (milligram per deciliter), triglycerides (milligrams per deciliter) and fasting glucose levels (milligrams per deciliter) were enzymatically measured using a Hitachi Modular 7600 automatic analyzer (Hitachi Ltd., Tokyo, Japan). The fasting insulin (micro-International units per milliliter) and serum vitamin D (nanograms per milliliter) concentrations were measured using immunoradiometric and radioimmunoassays using a gamma-counter (1470 Wizard; PerkinElmer, Waltham, MA, USA). The direct measurement of low-density lipoprotein (LDL) cholesterol was limited, and it was mainly calculated using the Friedewald equation (i.e., LDL cholesterol = total cholesterol − HDL cholesterol − triglyceride/5) [15]. Insulin resistance was evaluated using the homeostasis model assessment: estimated insulin resistance (HOMA-IR) index (i.e., HOMA-IR = [fasting plasma glucose] × [fasting plasma
insulin] × 0.055 /22.5) and homeostasis model assessment: estimated beta cell function (HOMA-beta) index (i.e., HOMA-beta = 20 × [fasting plasma insulin / ([fasting plasma glucose] × 0.055–3.5]) [16].

Assessment of BMD
The whole-body dual-energy x-ray absorptiometry (DXA) survey began in July 2008 and ended in May 2011. The BMDs of the lumbar spine, left total hip, and left femoral neck, and body composition including percent fat mass, were measured using DXA (Discovery-W; Hologic Inc., Waltham, MA, USA). As described previously [14], for the lumbar spine, the mean value of BMDs of L1–L4 was selected for analysis according to the recommendation of the International Society for Clinical Densitometry [17]. The BMD of the right femur was used when the left femur could not be measured (e.g., postoperative state, fracture, deformity, or malformation). The technicians performing the BMD measurements tested the precision based on duplicate or triplicate measurements in 30 or 15 participants, respectively. The precision error was calculated as the percentage coefficient of variation (CV %). The precision errors allowed for the total hip, femur neck, and lumbar vertebrae were 1.8%, 2.5%, and 1.9%, respectively [14].

Assessments and definition of DM/prediabetes and duration of DM
The following definitions were obtained from the Division of Health and Nutritional Survey of the KCDCP. DM was defined by either a self-reported history of DM diagnosis and current usage of insulin or oral hypoglycemic agents, or by a ≥126 mg/dL fasting blood glucose level or ≥6.5% glycated hemoglobin (HbA1c) level. Prediabetes was defined as ≥100–125 mg/dL fasting blood glucose, or ≥5.7–6.5 HbA1c levels. DM duration was calculated by subtracting the age at the time of DM diagnosis from the age at the time of the investigation. Data without time-diagnosed diabetes were excluded.

Statistical analysis
Statistical analyses were carried out using STATA 14.0 (StataCorp, College Station, TX, USA) with the SVY commands to account for the complex sampling design and include sample weight, which enabled the results to represent the entire national male population > 50 years [13]. All continuous data were presented as the mean ± standard error (SE). All categorical data were presented as numbers and percentages. To compare the participants’ characteristics of the study among control, groups with prediabetes and DM, the analysis of variance (ANOVA) test and \( \chi^2 \) test for continuous and categorical variables, respectively, were used. Multivariable linear regression analyses were performed to determine whether the BMD at each measured site differed based on the DM status and duration. In model 1, we adjusted for major factors, such as age and BMI. Model 2 was also adjusted for alcohol consumption; serum vitamin D concentration; smoking status; triglyceride levels, HDL cholesterol levels and total cholesterol levels, hypertension diagnosis, physical activity.
level, and HOMA-IR index scores. LDL cholesterol was not included as a covariate in model 2 because a significant collinearity was found between LDL and total cholesterol levels. Bonferroni’s correction was performed for comparisons between the control group and groups with prediabetes and DM. The reported probability values are two-sided, and results with a \( p \)-value < 0.05 were considered statistically significant.

Results
Baseline characteristics of the participants based on type 2 DM status
Among all participants aged ≥50 years of the 2008–2011 KNHANES, 1037 (29.76%) men had prediabetes, and 644 (18.57%) men had DM. Table 1 shows the baseline characteristics of the control, participants with prediabetes and DM. Patients with diabetes were slightly older

Table 1 Weighted baseline characteristics of study participants from the KNHANES (2008–2011)

|                          | Normal \( n=1702(51.67)^b \) | Prediabetes \( n=1037(29.76)^b \) | Diabetes \( n=644(18.57)^b \) |
|--------------------------|-------------------------------|------------------------------------|-------------------------------|
| Age (years)              | 60.46 ± 0.27                  | 60.63 ± 0.32                       | 61.59 ± 0.41                  |
| Weight (kg)              | 65.40 ± 0.29                  | 68.25 ± 0.40                       | 68.97 ± 0.51                  |
| Height (cm)              | 167.11 ± 0.18                 | 167.46 ± 0.24                      | 166.72 ± 0.29                 |
| BMI (kg/m²)              | 23.39 ± 0.09                  | 24.29 ± 0.11                       | 24.78 ± 0.16                  |
| Fat mass (%) (n = 3298)  | 21.74 ± 0.15                  | 23.03 ± 0.18                       | 23.49 ± 0.25                  |
| Low income (n = 3342) n (%) | 484 (11.87)                   | 246 (5.83)                         | 217 (5.53)                    |
| Physical activity n, (%)  | 429 (25.90)                   | 259 (23.59)                        | 159 (24.23)                   |
| low                      |                               |                                    |                               |
| moderate                 | 663 (36.97)                   | 417 (40.40)                        | 272 (43.13)                   |
| high                     | 608 (37.12)                   | 360 (36.01)                        | 211 (32.64)                   |
| 1700                     | 642                            |                                    | 0.65                          |
| Smoking history n, (%)   | 305 (18.11)                   | 191 (16.41)                        | 101 (14.28)                   |
| never                    | 817 (45.87)                   | 525 (48.27)                        | 327 (47.22)                   |
| past                     | 580 (36.02)                   | 321 (35.33)                        | 216 (38.50)                   |
| current                  | 1702                           | 1037                               | 644                           |
| alcohol consumption (g/day) | 13.42 ± 0.56                  | 16.24 ± 0.77                       | 15.23 ± 1.14                  |
| hypertension^a           | 848(44.13)                    | 705(34.1)                          | 446(21.7)                     |
| fasting glucose (mg/dl)  | 90.99 ± 0.17                  | 107.03 ± 0.27                      | 141.38 ± 1.96                 |
| fasting insulin (IU/mL)  | 8.74 ± 0.13                   | 10.40 ± 0.19                       | 10.83 ± 0.33                  |
| (n = 2927)               |                                |                                    |                               |
| HbA1c (n = 1001)         | 5.45 ± 0.02                   | 5.91 ± 0.03                        | 7.21 ± 0.07                   |
| HOMA-IR (n = 2927)^a     | 1.95 ± 0.03                   | 2.75 ± 0.05                        | 3.74 ± 0.12                   |
| HOMA-beta (n = 2927)^a    | 120.59 ± 1.89                 | 86.18 ± 1.53                       | 58.97 ± 6.70                  |
| DM duration (years)      | 8.43 ± 0.34                   |                                    |                               |
| (n = 505)                |                                |                                    |                               |
| total cholesterol (mg/dl)| 186.99 ± 1.09                 | 192.80 ± 1.40                      | 181.16 ± 2.00                 |
| HDL-C (mg/dl)            | 45.26 ± 0.36                  | 45.72 ± 0.43                       | 42.27 ± 0.49                  |
| LDL-C (mg/dl)            | 111.77 ± 1.15                 | 111.11 ± 1.46                      | 99.98 ± 2.03                  |
| Triglyceride (mg/dl)     | 149.80 ± 4.87                 | 179.85 ± 5.37                      | 194.53 ± 7.85                 |
| serum vitamin D (ng/mL)  | 21.38 ± 0.29                  | 21.17 ± 0.34                       | 20.52 ± 0.41                  |

^aThe data are presented as n (%) or the means ± standard error (SE). \( n \) = unweighted; \( N \) = the size of Korean population estimated using sample weights; physical activity level = low (<600 MET minutes per week), moderate (≥600-<3000 MET minutes per week), high (≥3000 MET minutes per week); hypertension = diagnosis and current usage of antihypertensive drug or ≥140 mmHg systolic BP, or ≥90 mmHg diastolic BP; HOMA-IR = \([\text{fasting plasma glucose}] \times \text{fasting insulin} \times 0.055/22.5\); HOMA-beta = 20 × (fasting plasma insulin / (fasting plasma glucose) × 0.055-3.5); HbA1c = glycated hemoglobin; LDL-C = low-density lipoprotein cholesterol; HDL-C = high-density lipoprotein cholesterol

^bThe prevalence (%) are presented weighted value
than men in other groups. Men who had prediabetes and diabetes were more likely to be overweight or obese have hypertension; have higher fasting glucose levels, HOMA-IR index scores, HDL and LDL cholesterol levels, triglyceride levels, and alcohol consumption; and have lower HOMA-beta index scores, than those in the control group (p < 0.05). The control, prediabetic, and diabetic groups differed in terms of BMD based on the World Health Organization’s criteria.

**Association between BMD and DM status**

The BMDs at various measured sites in the control, prediabetic, and diabetic groups were compared. Men with prediabetes and diabetes had higher lumbar spine and total hip BMDs than controls in the crude analysis. The prediabetic group had higher femoral neck BMDs than the control group. No significant differences in three BMD sites were found between the prediabetic and diabetic groups. In model 1, after adjusting for age and BMI, the prediabetic group had higher lumbar spine and total hip BMDs than the control group. After further adjustments for all clinically relevant covariates (model 2), the men with DM and men with prediabetes had higher lumbar spine, total hip, and femoral neck BMDs than controls. Similarly, no significant difference at three BMD sites were found between the prediabetic and diabetic groups in both models 1 and 2 (Table 2).

**Baseline characteristics of the participants based on DM duration**

Table 3 shows the baseline characteristics of the participants with diabetes duration of ≤ 5 years and those with a disease duration of > 5 years. A total of 505 people were identified for type 2 DM duration: 235 participants with a disease duration of ≤ 5 years and 270 with longer DM duration. No significant differences between the two groups were found in terms of insulin-associated factors, BMI, fat mass, total cholesterol levels, and HDL and LDL cholesterol levels. However, longer DM duration participants were slightly older with a lower percentage of current smokers and had higher fasting glucose and HbA1c levels than those with shorter DM duration.

**Association between BMD and DM duration**

The BMDs at various measured sites were compared between the participants with DM duration of ≤ 5 years and those with disease duration of > 5 years. The group with longer DM durations had lower total hip and femoral neck BMDs than those with shorter DM durations in the crude analysis. The strength of the association between total hip BMD and DM duration declined after further adjustments; however, the group with longer DM durations had lower femoral neck BMDs than those with shorter DM durations in both models 1 and 2 (Table 4).

**Discussion**

In the present study, the prediabetic and diabetic groups had higher mean BMDs at all measured sites than the control group. The BMDs in men with prediabetes were similar to those in men with diabetes in all cases. However, men with diabetes with a disease duration of > 5 years had lower mean femoral neck BMDs than those with a

---

**Table 2** Comparison of BMDs (g/cm²) at various measured sites

|                  | Normal (n=3383, N=4,370,109) | PreDM (n=1702, 51.67%) | DM (n=644, 18.57%) | p-value | p-value | p-value |
|------------------|-------------------------------|------------------------|-------------------|---------|---------|---------|
|                  | Normal                        | PreDM                  | DM                |         |         |         |
|                  | n=1702 (51.67%)               | n=1037 (29.76%)        | n=644 (18.57%)    |         |         |         |
| Crude            |                               |                        |                   |         |         |         |
| lumbar spine     | 0.928±0.004                   | 0.966±0.006            | 0.973±0.008       | <0.001* | <0.001* | 0.478   |
| total hip        | 0.924±0.003                   | 0.951±0.005            | 0.950±0.006       | <0.001* | <0.001* | 0.872   |
| femoral neck     | 0.751±0.003                   | 0.768±0.005            | 0.762±0.006       | 0.004*  | 0.091   | 0.448   |
| Model 1a         |                               |                        |                   |         |         |         |
| lumbar spine     | 0.923±0.001                   | 0.962±0.001            | 0.967±0.002       | 0.001*  | 0.006*  | 0.994   |
| total hip        | 0.911±0.002                   | 0.940±0.002            | 0.936±0.003       | 0.014*  | 0.226   | 0.434   |
| femoral neck     | 0.738±0.001                   | 0.757±0.002            | 0.749±0.002       | 0.228   | 0.702   | 0.222   |
| Model 2b         |                               |                        |                   |         |         |         |
| lumbar spine     | 0.922±0.001                   | 0.967±0.002            | 0.969±0.002       | <0.001* | 0.001*  | 0.765   |
| total hip        | 0.912±0.002                   | 0.944±0.002            | 0.939±0.002       | <0.001* | <0.001* | 0.316   |
| femoral neck     | 0.738±0.002                   | 0.760±0.002            | 0.752±0.003       | 0.046   | 0.034   | 0.707   |

*aModel 1: adjusted for age and BMI  
*bModel 2: adjusted for age, BMI, alcohol consumption, serum vitamin D, smoke status, triglyceride, HDL-cholesterol, total cholesterol, hypertension, physical activity, and HOMA-IR  
*cThe data are presented as means ± SE. n = unweighted; N = the size of Korean population estimated using sample weights  
*dP<0.0167 compared to 3 groups by Bonferroni’s correction"
Asian people develop diabetes at a lower degree of obesity and at younger ages and experience chronic diabetic complications [18]. In addition, some studies in Japan [19] and Korea [20] have showed that Asian patients with type 2 DM have lower BMI and decreased β-cell function compared with European and American patients. Current study showed that each groups had similar BMI in overweight range, but not obesity. Therefore a study on the relationship between type 2 diabetes and osteoporosis in Asian population would be good in isolating the effect of obesity.

The association between BMD and type 2 DM remains unclear. However, the results of the current study are consistent with those of previous studies in that DM patients have higher BMDs [21–23]. This study showed that men with prediabetes had higher BMDs than controls. Moreover, in this study, men with prediabetes and DM showed similar fasting insulin levels. Excessively high insulin level in the blood has been reported to be associated with increased bone mass [24] because of the

### Table 3 Weighted baseline characteristics of the diabetes group based on diabetic duration

|                          | DM duration ≤ 5 years | DM duration > 5 years | p-value |
|--------------------------|-----------------------|-----------------------|---------|
|                          | n = 235 (51.01)       | n = 270 (48.99)       |         |
| Age (years)              | 60.45 ± 0.60          | 62.79 ± 0.64          | 0.008   |
| Weight (kg)              | 70.25 ± 0.90          | 68.06 ± 0.69          | 0.054   |
| Height (cm)              | 167.24 ± 0.56         | 166.33 ± 0.43         | 0.199   |
| BMI (kg/m2)              | 25.06 ± 0.26          | 24.56 ± 0.21          | 0.132   |
| Fat mass (%) (n = 495)   | 23.66 ± 0.43          | 23.58 ± 0.37          | 0.879   |
| Low income (n = 497) n, (%) | 79 (26.95%)           | 93 (34.15%)           | 0.124   |
| Physical activity n, (%)a | low 59 (21.82)              | 66 (27.29)              |         |
|                          | moderate 95 (44.34)    | 115 (40.35)           |         |
|                          | high 80 (33.84)        | 88 (32.38)            |         |
| Smoker (%)               | never 45 (18.62)       | 40 (12.41)            | 0.204   |
|                          | past 100 (34.80)       | 153 (55.73)           |         |
|                          | current 90 (46.58)     | 77 (31.86)            |         |
| alcohol (g/day)          | 15.96 ± 1.78          | 12.90 ± 1.61          | 0.204   |
| Hypertension (%)a        | 34.98                 | 30.29                 | 0.201   |
| fasting glucose          | 134.42 ± 2.98         | 144.06 ± 3.82         | 0.047   |
| fasting insulin (n = 432)| 10.24 ± 0.49          | 10.66 ± 0.45          | 0.528   |
| HbA1c (n = 488)          | 6.97 ± 0.09           | 7.54 ± 0.11           | <0.001  |
| HOMA-IR (n = 432)a       | 3.39 ± 0.21           | 3.70 ± 0.16           | 0.243   |
| HOMA-beta (n = 432)a     | 67.94 ± 5.39          | 51.60 ± 17.91         | 0.383   |
| total cholesterol (mg/dl)| 175.71 ± 2.79         | 179.53 ± 3.21         | 0.37    |
| HDL-C (mg/dl)            | 42.53 ± 0.78          | 41.79 ± 0.76          | 0.498   |
| LDL-C (mg/dl)            | 98.73 ± 2.56          | 100.91 ± 2.58         | 0.549   |
| Triglyceride (mg/dl)     | 172.25 ± 9.44         | 182.15 ± 9.12         | 0.365   |
| serum vitamin D (ng/mL)  | 20.27 ± 0.55          | 20.60 ± 0.59          | 0.69    |

*The data are presented as n (%) or the means ± standard error (SE). n = unweighted; N = the size of Korean population estimated using sample weights; physical activity level = low (<600 MET minutes per week), moderate (≥600-<3000 MET minutes per week), high (≥3000 MET minutes per week); hypertension = diagnosis and current usage of antihypertensive drug or ≥140 mmHg systolic BP, or ≥90 mmHg diastolic BP; HOMA-IR = [fasting plasma glucose] × [fasting insulin] ×0.055 /22.5; HOMA-beta = 20 × [fasting plasma insulin / ([fasting plasma glucose] × 0.055-3.5); HbA1c = glycated hemoglobin; LDL-C = low-density lipoprotein cholesterol; HDL-C = high-density lipoprotein cholesterol

*bThe prevalence (%) are presented weighted value.
anabolic effects of insulin [25] and increase in free sex hormone levels [26]. Although prediabetes is not considered a disease, insulin resistance in prediabetes will affect bone mass and microstructure [12].

Bone fragility results from decreased BMD and alterations in bone microstructure [3]. Assessing the macro-geometry of cortical bone and the microarchitecture of the trabecular bone is difficult owing to the use of quantitative CT or MRI. In clinical setting, the gold standard of bone strength measurement is DXA and BMD remains a significant predictor of fracture risk in type 2 DM, that is, independent of trabecular bone score and DM itself [27].

Elevated fasting insulin levels play a key role in DM development, and they mostly result in increased bone mass. In complicated conditions, such as advanced type 2 DM, elevated insulin levels have an unexpected effect. As insulin resistance increases, the fasting insulin levels are inversely related to BMD, and this relationship becomes more significant as the degree of insulin resistance increases [12]. In advanced type 2 DM requiring insulin, pancreatic β-cell function certainly decreased. However, the exact timing of this phenomenon remains to be determined. A Korean prospective cohort study [20] reported on the role of β-cell dysfunction on DM development, focusing on Asian populations. Insulin levels possibly increased and then decreased at some point, and the bone density may have become weak at this point.

In the present study, insulin levels were similar in prediabetes and diabetes and in two groups with different duration of disease. It was significantly different that fasting glucose levels in prediabetes and diabetes, and HbA1c levels between men with diabetes duration of ≤5 years and those with diabetes duration > 5 years. High blood glucose induces formation of advanced glycation end-products (AGE), with negative effects on structural proteins such as type I collagen, the main bone matrix protein. AGE may also reduce bone strength by impairing bone formation [28]. Most of the recent studies have confirmed decreased levels of bone turnover markers in patients with DM [3]. The previous research on mechanisms of type 2 DM showed that action on bone with long-term high glucose levels could lower the turnover, resulting in unfavorable bone balance.

Researchers have generally neglected osteoporosis in men for some time, and many studies have focused on women as participants. One study showed that non-obese women with type2 DM had lower BMD than control participants matched for BMI [29]. In the present study, we investigated the correlation between BMD and BMI in the group with DM. Our results confirmed the absence of such a correlation. Obese patients with type 2 DM have increased BMD, and evidence indicates that older white women, but not men or black women, with diabetes exhibited more rapid bone loss at the femoral neck and total hip than those with normal glucose homoeostasis [30]. Type 2 DM has been associated with higher bone loss at the femoral neck than at the total hip in white women even after adjusting for weight loss. Although white women with type 2 DM had higher baseline BMDs, they still exhibited increased bone loss rate, particularly at the femoral neck, than those with normal glucose homoeostasis. This seemingly contradictory finding

### Table 4
Comparison of BMDs (g/cm²) at various measured sites based on diabetes duration

|                    | Crude                    | Model 1 | Model 2 | p-value |
|--------------------|--------------------------|---------|---------|---------|
|                    |                           | lumbar spine (n = 481) | lumbar spine | lumbar spine |
|                    |                           | 0.979 ± 0.013          | 0.976 ± 0.002 | 0.976 ± 0.003 | 0.976 ± 0.003 | 0.906  |
|                    |                           | total hip              | 0.968 ± 0.009 | 0.953 ± 0.004 | 0.953 ± 0.005 | 0.953 ± 0.005 | 0.026* |
|                    |                           | femoral neck           | 0.786 ± 0.009 | 0.770 ± 0.004 | 0.770 ± 0.004 | 0.770 ± 0.004 | 0.001* |
|                    |                           |                      |          | 0.979 ± 0.013 | 0.976 ± 0.002 | 0.976 ± 0.003 | 0.976 ± 0.003 | 0.906  |
|                    |                           |                      |          | 0.968 ± 0.009 | 0.953 ± 0.004 | 0.953 ± 0.005 | 0.953 ± 0.005 | 0.026* |
|                    |                           |                      |          | 0.786 ± 0.009 | 0.770 ± 0.004 | 0.770 ± 0.004 | 0.770 ± 0.004 | 0.001* |
|                    | Model 1                  | lumbar spine           | 0.976 ± 0.003 | 0.976 ± 0.003 | 0.976 ± 0.003 | 0.976 ± 0.003 | 0.906  |
|                    |                           | total hip              | 0.955 ± 0.005 | 0.933 ± 0.004 | 0.933 ± 0.004 | 0.933 ± 0.004 | 0.337  |
|                    |                           | femoral neck           | 0.773 ± 0.004 | 0.738 ± 0.004 | 0.738 ± 0.004 | 0.738 ± 0.004 | 0.018* |

*Model 1: adjusted for age and BMI
*Model 2: adjusted for age, BMI, alcohol consumption, serum vitamin D, smoke status, triglyceride, HDL-cholesterol, total cholesterol, hypertension, physical activity, and HOMA-IR
*Data are presented as means ± SE. n = unweighted; N = the size of Korean population estimated using sample weights.
*Statistically significant (p<0.05) on the basis of the multivariable linear regression test.
of higher cross-sectional BMD being associated with more rapid bone loss may reflect the net result of the positive effects of excessive weight and hyperinsulinemia on bones combined with the negative effects of longer diabetes duration [31].

Possible explanations for significant reduction of femoral BMD are existing literature on bone loss and cortical porosity. Pentosidine is the best-studied AGEs to date. The content of pentosidine in cortical and trabecular bone was higher in patients with femoral neck fractures than in age-matched controls [3]. These women with prior fractures have significantly lower femoral neck volumetric BMD, a trend towards larger bone volume and thinner cortices on quantitative CT, and higher serum levels of sclerostin than women without fractures and nondiabetic controls with fractures(increases of 31.4% and 25.2%, respectively) [32].

Patients with type 2 DM have a significantly higher fracture risk than the general population [3, 5]. Men with type 2 DM have lower muscle mass and strength, contributing to the higher incidence of falls and fractures observed in type 2 DM patients [33]. Hip fracture is the most serious osteoporotic fracture, and our study shows that the femoral neck BMD was lower in the group with a DM duration of > 5 years than in those with a DM duration of ≤5 years. Previous studies showed that patients with type 2 DM have an increased fracture risk in the hip [5, 22]. Furthermore, another study revealed that women with a DM duration of ≥10 years have particularly high major osteoporotic and hip fracture risks [33].

This study used relatively large sample sizes representing national population-based data. The sample design and size were also estimated using the methods described in the KNHANES. Therefore, the results can be generalized to whole Korean diabetics. This study is the first to indicate decreased femoral neck BMD in long-time DM in Asia, which is consistent with the findings of previous studies. Current study demonstrated decreased BMD by DXA with duration of type 2 DM different from the earlier studies. However, several limitations should be considered when interpreting the results of this study. The intrinsic nature of cross-sectional design studies precludes this study from conclusively determining any potential causal relationships. The KNHANES was conducted annually, and the subjects were those who were not able to undergo DXA between 2008 and 2011, despite the introduction of DXA in 2008. This study did not consider the anti-diabetic medication in the group with DM; therefore, the effects of drugs are unknown. The reduction in BMD associated with type 2 DM duration requires further study. Five-year type 2 DM duration is a very short period to evaluate its effects on BMD. Moreover, femoral neck BMD decreased in participants with relatively short-term type 2 DM; thus, caution is needed when interpreting the results.

**Conclusions**

This study aimed to assess the association between BMD and type 2 DM status in middle-aged or older men based on a nationwide survey. DM duration was significantly associated with reduced femoral neck BMD in men after adjusting for associated factors, such as age, BMI, and serum vitamin D level.

**Abbreviations**

AGE: Advanced glycation end-products; BMD: Bone mineral density; BMI: Body mass index; BP: Blood pressure; CV: Coefficient of variation; DM: Diabetes mellitus; DXA: Dual-energy X-ray absorptiometry; Hba1c: Glycated hemoglobin; HDL: High-density lipoprotein; HOMA-beta: Homeostasis model assessment: estimated beta cell function; HOMA-IR: Homeostasis model assessment: estimated insulin resistance; KCDCP: Korea Centers for Disease Control and Prevention; KNHANES: Korea National Health and Nutritional Examination Survey; LDL: Low-density lipoprotein; MET: Metabolic equivalent of task

**Acknowledgments**

We are grateful to all study participants for their contributions.

**Availability of data and materials**

KNHANES was conducted after the ethical approval was granted by the Institutional Review Board of the Korea Centers for Disease Control and Prevention (approval numbers: 2008-04EX01-01, 2009-01CON-03-01; 2010-02CON-21-01, 2011-02CON-06C; https://knhanes.cdc.go.kr/knhan/n/man.do). The datasets generated and/or analysed during the current study are available in the Korea National and Health Examination Survey repository, https://knhanes.cdc.go.kr/knhan/n/man.do. The data from KNHANES is open data for research purposes.

**Authors’ contributions**

All authors read and approved the final manuscript. Conceptualization: MJ, HK, SL, JSK, BO. Data curation: MJ, HK, SL. Formal analysis: MJ, HK, JSK, BO. Investigation: MJ, HK, BO. Methodology: MJ, SO, JSK, BO. Software: MJ, HK, SL, SO. Supervision: SO, JSK, BO. Validation: SO, JSK, BO. Writing – original draft: MJ. Writing – review & editing: SO, JSK, BO.

**Ethics approval and consent to participate**

This study was approved by the Institutional Review Board of the Seoul Metropolitan Government – Seoul National University Boramae Medical Center (approval number: 07–2018-19). Since this data is anonymous, it can’t be approved by the individual. Therefore, the consent form was waived.

**Consent for publication**

Not applicable.

**Competing interests**

Miso Jang, Hyunkyung Kim, Shorry Lea, Sohee Oh, Jong Seung Kim, and Bumjo Oh declare that they have no competing of interest.

**Publisher’s Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Author details**

1Department of Family Medicine and Center for Cancer Prevention and Detection, Hospital, National Cancer Center, 323, Ilsan-ro, Ilsan-dong, Goyang-si, Gyeonggi-do 10408, Republic of Korea. 2Department of Family Medicine, Dohi Hospital, 60, Hi park 2-ro, Ilsanseo-gu, Goyang-si, Gyeonggi-do 10244, Republic of Korea. 3Center for Health Promotion, Cheil General Hospital, 17, Seoae-ro 1-gil, Jung-gu, Seoul 04619, Republic of Korea. 4Department of Biostatistics, SMG-SNU Boramae Medical Center, 20, Boramae-ro 5-gil, Dongjak-gu, Seoul 07061, Republic of Korea. 5Department of Family Medicine, SMG-SNU Boramae Medical Center, 20, Boramae-ro 5-gil, Dongjak-gu, Seoul 07061, Republic of Korea.
References

1. Federation ID. IDF diabetes atlas. Brussels: International Diabetes Federation; 2013.
2. Jovanović O, Kanis JA. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int. 2006;17(12):1726–33.
3. Napolitano N, et al. Mechanisms of diabetes mellitus-induced bone fragility. Nat Rev Endocrinol. 2017;13(4):208–19.
4. Yamaguchi T, Sugimoto T. Bone metabolism and fracture risk in type 2 diabetes mellitus [review]. Endocr J. 2011;58(8):613–24.
5. Schwartz AV, et al. Association of BMD and FRAX score with risk of fracture in older adults with type 2 diabetes. JAMA. 2011;305(21):2184–92.
6. Willson T, et al. The clinical epidemiology of male osteoporosis: a review of the recent literature. Clin Eng. 2015;7:65.
7. McGuigan FE, Besjakov J, Åkesson K. Hip fracture in men—survival and subsequent fractures: a cohort study with 22-year follow-up. J Am Geriatr Soc. 2011;59(5):806–13.
8. Byles JP, Miller DC, Scharer WD. Gender differences in risk taking: A meta-analysis. Am Psychol Assoc. 1999.
9. Alswat K, Adler SM. Gender differences in osteoporosis screening: retrospective analysis. Arch Osteoporos. 2012;7:331–3.
10. Park EJ, et al. Prevalence of osteoporosis in the Korean population based on the Korea National Health and nutrition examination survey (KNHANES), 2008-2011. Yonsei Med J. 2014;55(4):1049–57.
11. Kim Y, Kim JH, Cho DS. Gender difference in osteoporosis prevalence, awareness and treatment: based on the Korea National Health and nutrition examination survey 2008–2011. J Korean Acad Nurs. 2015;45(2):
12. Shin D, et al. Association between insulin resistance and bone mass in men. J Clin Endocrinol Metab. 2014;99(4):988–95.
13. Kweon S, et al. Data resource profile: the Korea national health and nutrition examination survey (KNHANES). Int J Epidemiol. 2014;43(1):69–77.
14. Lim Y, et al. Association of bone mineral density and diabetic retinopathy in diabetic subjects: the 2008-2011 Korea National Health and nutrition examination survey. Osteoporos Int. 2016;27(7):2249–57.
15. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18(6):499–502.
16. Matthews D, et al. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412–9.
17. Simonelli C, et al. Dual-energy x-ray absorptiometry technical issues: the 2007 ISCD official positions. J Clin Densitom. 2008;11(1):109–22.
18. Yoon K-H, et al. Epidemic obesity and type 2 diabetes in Asia. Lancet. 2006;368(9548):1681–8.
19. Morimoto A, et al. Impact of impaired insulin secretion and insulin resistance on the incidence of type 2 diabetes mellitus in a Japanese population: the Sahoku study. Diabetologia. 2013;56(8):1671–9.
20. Ohn JH, et al. 10-year trajectory of beta-cell function and insulin sensitivity in the development of type 2 diabetes: a community-based prospective cohort study. Lancet Diabet Endocrinol. 2016;4(1):27–34.
21. Ma L, et al. Association between bone mineral density and type 2 diabetes mellitus: a meta-analysis of observational studies. Eur J Epidemiol. 2012;27(5):319–32.
22. Vestergaard P. Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes—a meta-analysis. Osteoporos Int. 2007;18(4):427–44.
23. Leidi-Bruckner G, et al. Prevalence and determinants of osteoporosis in patients with type 1 and type 2 diabetes mellitus. BMC Endocr Diord. 2014;14:33.
24. De Leffe L, et al. Bone mineral density and fracture risk in type 2 diabetes mellitus: the Rotterdam study. Osteoporos Int. 2005;16(12):1713–20.
25. Thrailkill KM, et al. Is insulin an anabolic agent in bone? Dissecting the diabetic bone for clues. Am J Physiol Endocrinol Metab. 2005;289(5):E735–45.
26. Dennison E, et al. Type 2 diabetes mellitus is associated with increased axial bone density in men and women from the Hertfordshire cohort study: evidence for an indirect effect of insulin resistance? Diabetes. 2004;53(11):1963–8.
27. Leslie WD, et al. TBS (trabecular bone score) and diabetes-related fracture risk. s. 2013;98(2):602–9.
28. Napoli N, et al. The alliance of mesenchymal stem cells, bone, and diabetes. Int J Endocrinol. 2014, 2014.
29. Zhou Y, et al. Prevalence and predictors of osteopenia and osteoporosis in postmenopausal Chinese women with type 2 diabetes. Diabetes Res Clin Pract. 2010;90(3):261–9.
30. Schwartz AV, et al. Diabetes and bone loss at the hip in older black and white adults. J Bone Miner Res. 2005;20(4):596–603.
31. Sellmeyer DE, et al. Skeletal metabolism, fracture risk, and fracture outcomes in type 1 and type 2 diabetes. Diabetes. 2016;65(7):1757–66.
32. Heilmeier U, et al. Volumetric femoral BMD, bone geometry, and serum sclerostin levels differ between type 2 diabetic postmenopausal women with and without fragility fractures. Osteoporos Int. 2015;26(4):1283–93.
33. Majumdar SR, et al. Longer duration of diabetes strongly impacts fracture risk assessment: the Manitoba BMD cohort. J Clin Endocrinol Metab. 2016;101(11):4480–96.

Received: 19 September 2017 Accepted: 24 August 2018
Published online: 05 September 2018

Ready to submit your research? Choose BMC and benefit from:
• fast, convenient online submission
• thorough peer review by experienced researchers in your field
• rapid publication on acceptance
• support for research data, including large and complex data types
• gold Open Access which fosters wider collaboration and increased citations
• maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.
Learn more biomedcentral.com/submissions